Risk Factors and Impact MASLD in Patients With IBD

Not yet recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2025

Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions
DEVICE

FibroScan

All the study population will be submitted to Fibroscan examination with CAP (Echosens FibroScan® Compact 530). To evaluate steatosis and fibrosis, participants will be asked to fast for at least 3 hours before the test. To capture a controlled attenuation parameter (CAP) score and liver stiffness measurement (LSM), 10 valid scans per subject will be needed.

All Listed Sponsors
lead

Assiut University

OTHER

NCT06328452 - Risk Factors and Impact MASLD in Patients With IBD | Biotech Hunter | Biotech Hunter